MedTrace Logo

Pancreatic Cancer Early Detection Consortium

NCT04970056 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Conditions

Sponsors & Collaborators

  • Arbor Research Collaborative for Health

    lead OTHER

Principal Investigators

  • Diane Simeone, MD · UC San Diego Moores Cancer Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • United States
  • Australia
  • Canada
  • Hungary
  • Iceland
  • Israel
  • Italy
  • Singapore
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970056 on ClinicalTrials.gov